Immunovant
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $160 | $0 |
Gross Profit | -107 | 80 | -99 | |
EBITDA | -131,657 | -127,117 | -113,716 | -114,203 |
EBIT | -131,762 | -127,224 | -113,825 | -114,302 |
Net Income | -126,502 | -120,613 | -106,449 | -111,122 |
Net Change In Cash | 0 | 0 | 160 | 0 |
Free Cash Flow | -102,515 | -117,411 | -110,838 | -100,571 |
Cash | 521,870 | 598,912 | 713,971 | 374,685 |
Basic Shares | 173,643 | 170,872 | 151,574 | 146,922 |
Annual Financials
| Values in thousands | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -377 | -231 | -1,324 | -1,232 |
EBITDA | -437,775 | -269,978 | -208,083 | -155,907 |
EBIT | -438,152 | -270,209 | -208,276 | -156,033 |
Net Income | -413,840 | -259,336 | -210,960 | -156,730 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -117,505 | 93,763 | ||
Free Cash Flow | -376,633 | -214,587 | -188,390 | -106,366 |
Cash | 713,971 | 635,365 | 376,532 | 493,817 |
Basic Shares | 151,574 | 138,100 | 123,075 | 109,679 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.73 |
2025-06-30 | -$0.71 |
2025-03-31 | -$0.64 |
